WO2016104923A1 - 인유두종 바이러스의 바이러스 유사 입자 제조방법 - Google Patents
인유두종 바이러스의 바이러스 유사 입자 제조방법 Download PDFInfo
- Publication number
- WO2016104923A1 WO2016104923A1 PCT/KR2015/010740 KR2015010740W WO2016104923A1 WO 2016104923 A1 WO2016104923 A1 WO 2016104923A1 KR 2015010740 W KR2015010740 W KR 2015010740W WO 2016104923 A1 WO2016104923 A1 WO 2016104923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- concentration
- nacl
- protein
- salt
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
Definitions
- the present invention relates to a method for producing L1 virus-like particles (VLP) of human papilloma virus (HPV).
- VLP L1 virus-like particles
- HPV human papilloma virus
- HPVs human Papillomaviruses
- VLP Virus-Like Particles
- Korean Patent No. 10-0959145 documents disclose that a protein is precipitated by adding ammonium sulfate to a yeast lysate obtained by culturing a transformed yeast expressing HPV L1 protein, and then lysing it.
- a method for purifying HPV L1 protein by sequentially performing size-exclusion chromatography and cation-exchange chromatography on a protein precipitate is disclosed.
- the inventors have conducted studies on purification conditions that can increase production yield in producing and purifying HPV L1 protein on an industrial scale using a yeast expression system.
- the precipitate obtained by ammonium sulfate precipitation on the yeast product containing L1 protein was treated with 0.35-0.60 M of salt to remove impurities, and then chromatographed.
- This invention was completed by confirming that the refinement
- an object of the present invention is to provide a method for producing L1 virus-like particles of human papilloma virus.
- Another object of the present invention is to provide an L1 virus-like particle of the human papilloma virus prepared by the above method.
- the present invention provides a method for preparing L1 virus-like particles (VLP) of human papilloma virus (HPV), comprising the following steps:
- step (b) subjecting the product of the transformed yeast cultured in step (a) to ammonium sulfate precipitation to obtain a precipitate;
- step (d) chromatography the product of step (c) to obtain L1 protein.
- the inventors have conducted studies on purification conditions that can increase production yield in producing and purifying HPV L1 protein on an industrial scale using a yeast expression system. As a result, the precipitate obtained by ammonium sulfate precipitation on the yeast product containing L1 protein was treated with 0.35-0.60 M of salt to remove impurities, and then chromatographed. It was confirmed that the purification efficiency of can be significantly improved.
- step (a) of the present invention the transformed yeast expressing the L1 protein of HPV.
- Viable cells used to express the HPV L1 protein in the present invention is a yeast, for example Saccharomyces three Levy in my process jiae (Saccharomyces cerevisiae), my process as Saccharomyces Pas thoria Taunus (Saccharomyces pastorianus ), Saccharomyces sp . Schizosaccharomyces, Schizosaccharomyces pombe ) and baker's yeast.
- the transgenic yeast of the invention is Saccharomyces cerevisiae .
- the transformed yeast expressing the HPV L1 protein means a yeast cell transformed with an expression vector that successfully expresses the HPV L1 protein.
- the expression vector may include transcriptional or translational regulatory elements and other marker genes known in the art.
- HPV L1 protein expression transformed yeast of the present invention can be readily prepared using methods known in the art, such methods are described in US Pat. Nos. US 7250170, US 6613557, US 5888516, US 5871998, US 5618536, US5437951 and the like, the contents of these patent documents are incorporated herein by reference.
- the transformed yeast may be cultured by a method used in the art for the production of HPV L1 protein using yeast.
- the transformed yeast may be cultured in a medium to which at least one carbon source of glucose and galactose is added as a carbon source, and an exemplary medium used for culturing the transformed yeast is YPDG medium (yeast extract, peptone, glucose and Galactose).
- YPDG medium yeast extract, peptone, glucose and Galactose
- the transgenic yeast may be incubated for less than 96 hours (eg, 95 hours or less, 10-95 hours, 15-95 hours, 20-95 hours, or 24-95 hours) in a medium to which a carbon source is added.
- the L1 protein of HPV is HPV type 6a, HPV type 6b, HPV type 11, HPV type 16, HPV type 18, HPV type 31, HPV type 33, HPV type 35, HPV type 39 , HPV type 45, HPV type 51, HPV type 52, HPV type 56, HPV type 58 and HPV type 68.
- the L1 protein of HPV is HPV type 16 or HPV type 18.
- step (b) of the present invention the product of the transformed yeast cultured in step (a) (containing the L1 protein) is treated with ammonium sulfate to obtain a precipitate.
- the transformed yeast cultured in step (a) may be lysed and the yeast lysate may be treated with ammonium sulfate to obtain a precipitate.
- the lysing method of the cultured yeast cells can be used without limitation, methods for obtaining cell lysates known in the art, such as, for example, sonication, disruption by glass beads.
- yeast product is treated (added) with ammonium sulfate to precipitate the expressed protein, and the impurities are removed by centrifugation or the like.
- the concentration of ammonium sulphate treated in step (b) is 20-60% by weight. According to a more specific embodiment, the treatment concentration of the ammonium sulfate is 40-50% by weight or 42-48% by weight.
- the precipitate obtained by the ammonium sulphate precipitation in step (b) is incubated in a solution containing a salt (eg NaCl).
- a salt eg NaCl
- the precipitate obtained by the ammonium sulphate precipitation is diluted to 25-65 mg / mL by adding a buffer and then 0.5 M or more (e.g., 0.5-0.9 M, 0.6-0.9 M or 0.7-0.9 M) is added to NaCl and stirred for a period of time, followed by incubation for at least 12 hours (eg 18-20 hours).
- the temperature of the incubation may be 3-5 ° C (eg 4 ° C).
- step (c) of the present invention the ammonium sulphate precipitate is treated with 0.35-0.60 M of salt, and the resultant salt is incubated to form an insoluble protein as an impurity. Thereafter, by removing the insoluble protein formed, the purification efficiency of the HPV L1 protein is greatly improved.
- the salt treatment of 0.35-0.60 M in step (c) is a step that greatly contributes to the improvement of the purification efficiency of the HPV L1 protein (see Example 3). That is, when the insoluble protein produced in this step is removed by centrifugation, the purity of the VLP eluted in the next step chromatography can be greatly increased.
- step (c) the ammonium sulfate precipitate-containing solution incubated for a period of time in the presence of the above-described salt (eg, NaCl) is dialyzed in a buffer containing 0.35-0.60 M of salt. After incubation, impurities are made insoluble and removed.
- the buffer containing the salt of 0.35-0.60 M may include a nonionic surfactant.
- the nonionic surfactant may be included at a concentration of 0.001-0.1%.
- the concentration of ammonium sulphate precipitate to be treated with a salt of 0.35-0.60 M is 25-65 mg / mL.
- the concentration of such ammonium sulphate precipitate can be adjusted by mixing the buffer with the ammonium sulphate precipitate.
- the concentration of the ammonium sulfate precipitate is 28-62 mg / mL, 28-60 mg / mL, 28-55 mg / mL, 28-50, 30-62 mg / mL, 30-60 mg / mL, 30-55 mg / mL or 30-50 mg / mL.
- the salt is NaCl, KCl or Na 2 CO 3 .
- the concentration of the salt treated in step (c) is 0.35-0.60 M, 0.35-0.55 M, 0.35-0.50 M or 0.35-0.45 M; 0.40-0.60 M, 0.40-0.55 M, 0.40-0.50 M or 0.40-0.45 M; 0.45-0.60 M, 0.45-0.55 M or 0.45-0.50 M; Or 0.50-0.60 M or 0.50-0.55 M.
- the salt treated in step (c) is NaCl
- the treatment concentration of NaCl is 0.35-0.60 M or 0.35-0.55 M; 0.40-0.60 M or 0.40-0.55 M; Or 0.45-0.60 M or 0.45-0.55 M.
- the salt treated in step (c) is KCl
- the treatment concentration of KCl is 0.35-0.60 M or 0.40-0.60 M; 0.35-0.55 M; Or 0.55-0.60 M.
- the salt treated in step (c) is Na 2 CO 3
- the treatment concentration of Na 2 CO 3 is 0.35-0.60 M or 0.40-0.60 M; 0.35-0.55 M or 0.40-0.55 M; 0.35-0.50 M or 0.40-0.50 M; Or 0.35-0.45 M.
- the incubation temperature in step (c) is 25-34 ° C.
- the incubation temperature is 26-34 °C, 27-34 °C, 28-34 °C, 29-34 °C or 29.5-34 °C, according to another embodiment 25-33.5 °C, 26 -33.5 ° C, 27-33.5 ° C, 28-33.5 ° C, 29-33.5 ° C, 29.5-33.5 ° C or 30-33 ° C.
- the incubation time in step (c) is 21-27 hours. According to a more specific embodiment, the incubation time is 21-26 hours or 22-26 hours.
- step (d) of the present invention chromatography on the solution from which impurities are removed yields L1 protein.
- the solution from which impurities are removed through the above steps (a) to (c) is purified through chromatography, residual impurities may be removed very effectively.
- the chromatography is affinity chromatography or cation exchange chromatography.
- the affinity chromatography is heparin chromatography.
- heparin resin when performing heparin chromatography, heparin resin is first equilibrated with a suitable binding buffer before the result of step (c) is applied to the heparin resin column.
- the binding buffer preferably comprises NaCl and a nonionic surfactant (eg, Tweeen 80), with NaCl being preferably low in concentration (0.1-0.4 M).
- the sample is then subjected to heparin chromatography and the protein bound to the resin is eluted.
- the elution method is preferably a NaCl linear gradient, more preferably eluting impurities in a 0.33-0.66 M NaCl linear gradient, and then eluting the desired L1 protein at a 0.66-2 M NaCl linear gradient.
- the resin when cation exchange chromatography is performed, the resin is first equilibrated with a suitable binding buffer before the resultant is treated with 0.35-0.60 M of salt to remove impurities.
- the binding buffer preferably comprises NaCl and a nonionic surfactant (eg, Tweeen 80), with NaCl being preferably low in concentration (0.3-0.6 M).
- the sample is then subjected to cation exchange chromatography and the protein bound to the resin is eluted.
- the elution method is preferably NaCl step concentration gradient, more preferably eluting the desired L1 protein using an elution buffer containing 0.6 M, 0.7 M, 0.8 M and 1 M NaCl.
- Cation exchange chromatography can be carried out using a variety of resins, preferably using a cation exchanger combined with sulfo, sulfoalkyl (e.g. sulfomethyl, sulfoethyl and sulfopropyl), phosphate or phosphatealkyl functional groups. And most preferably, using a cation exchanger having a phosphate functional group bonded thereto.
- a cation exchanger having a phosphate functional group bonded thereto.
- the L1 protein fraction obtained through the chromatography process may be concentrated by a membrane filter.
- the chromatographic fractions can be concentrated using a membrane capable of cut-off a molecular weight of 50-100 kDa. Since VLPs having an average size of 50 nm are larger than other proteins, they are concentrated by not passing through the membrane, while most residual impurities are removed through the membrane.
- the salt treated in step (c) is NaCl
- the treatment concentration of NaCl is 0.35-0.60 M, 0.40-0.60 M, 0.45-0.60 M or 0.45-0.55 M.
- step (d) when the chromatography of step (d) is heparin chromatography, the salt treated in step (c) is KCl, and the treatment concentration of KCl is 0.35-0.60 M, 0.40-0.60 M , 0.45-0.60 M, 0.50-0.60 M or 0.55-0.60 M.
- step (d) when the chromatography of step (d) is heparin chromatography, the salt treated in step (c) is Na 2 CO 3, and the treatment concentration of Na 2 CO 3 is 0.35- 0.60 M or 0.40-0.60 M; 0.35-0.45 M; Or 0.55-0.60 M.
- step (d) when the chromatography of step (d) is cation exchange chromatography, the salt treated in step (c) is NaCl, and the treatment concentration of NaCl is 0.35-0.60 M, 0.40- 0.60 M or 0.45-0.55 M.
- step (d) when the chromatography of step (d) is cation exchange chromatography, the salt treated in step (c) is KCl, and the treatment concentration of KCl is 0.35-0.60 M, 0.35- 0.55 M, 0.35-0.50 M or 0.35-0.45 M.
- step (d) when the chromatography of step (d) is cation exchange chromatography, the salt treated in step (c) is Na 2 CO 3 , the treatment concentration of Na 2 CO 3 is 0.35 -0.60 M, 0.35-0.55 M, 0.35-0.50 M or 0.35-0.45 M.
- the present invention provides a method for preparing L1 virus-like particles (VLP) of HPV.
- the present invention performs one chromatographic process by first removing impurities through ammonium sulphate precipitation and then dialysis in a solution containing 0.35-0.60 M of salt to remove impurities. It is possible to produce HPV L1 protein with high purity.
- HPV antigen prepared according to the production method of the present invention is excellent in stability, it is suitable not only for vaccines but also for use as a raw material for HPV antibody diagnostic agents requiring high stability.
- Example 1 is a view related to Example 1, which shows the removal efficiency of insoluble protein according to the type of incubation temperature and the type of size up buffer in the purification of HPV type 16 L1 protein.
- FIG. 2 is a diagram related to Example 1 showing the removal efficiency of insoluble protein according to the type of incubation time and incubation time in the purification of HPV type 16 L1 protein.
- FIG. 3 is a view related to Example 1, and shows the purification pattern of each fraction when incubated at 35 ° C. in the insoluble protein removal step in the purification of HPV type 16 L1 protein.
- FIG. 4 is a diagram associated with Example 2, showing changes in purification yield of HPV Type 16 L1 protein with ammonium sulfate precipitation concentration.
- FIG. 5 is a view related to Example 3, which shows the result of purification by cation exchange chromatography after performing NaCl concentration at 0.15-0.6 M in a size-up step.
- FIG. 6 is a view related to Example 3, which shows purification yield purified by cation exchange chromatography after NaCl concentration was 0.15-0.6 M in the size-up step.
- Example 7 is a view related to Example 3, which shows the result of purification by cation exchange chromatography after performing KCl concentration at 0.15-0.6 M in the size-up step.
- Example 8 is a view related to Example 3, which shows the purification yield purified by cation exchange chromatography after performing KCl concentration at 0.15-0.6 M in the size-up step.
- Example 9 is a view related to Example 3, which shows the result of purification by cation exchange chromatography after performing Na 2 CO 3 concentration in the size-up step to 0.15-0.6 M.
- FIG. 9 is a view related to Example 3, which shows the result of purification by cation exchange chromatography after performing Na 2 CO 3 concentration in the size-up step to 0.15-0.6 M.
- FIG. 10 is a view related to Example 3, which shows purification yield purified by cation exchange chromatography after Na 2 CO 3 concentration in a size-up step is 0.15-0.6 M.
- FIG. 10 is a view related to Example 3, which shows purification yield purified by cation exchange chromatography after Na 2 CO 3 concentration in a size-up step is 0.15-0.6 M.
- FIG. 11 is a view related to Example 3, which shows the result of purification by affinity chromatography after NaCl concentration was performed at a size-up step of 0.15-0.6 M.
- FIG. 11 is a view related to Example 3, which shows the result of purification by affinity chromatography after NaCl concentration was performed at a size-up step of 0.15-0.6 M.
- Example 12 is a view related to Example 3, which shows the purification yield purified by affinity chromatography after performing NaCl concentration at 0.15-0.6 M in the size-up step.
- FIG. 13 is a view related to Example 3, which shows the result of purification by affinity chromatography after performing a KCl concentration of 0.15-0.6 M in a size-up step.
- FIG. 14 is a view related to Example 3, which shows the purification yield purified by affinity chromatography after performing KCl concentration at 0.15-0.6 M in the size-up step.
- Example 15 is a view related to Example 3, which shows the result of purification by affinity chromatography after performing Na 2 CO 3 concentration in the size-up step to 0.15-0.6 M.
- FIG. 15 is a view related to Example 3, which shows the result of purification by affinity chromatography after performing Na 2 CO 3 concentration in the size-up step to 0.15-0.6 M.
- FIG. 16 is a view related to Example 3, which shows the purification yield purified by affinity chromatography after performing Na 2 CO 3 concentration in the size-up step to 0.15-0.6 M.
- FIG. 16 is a view related to Example 3, which shows the purification yield purified by affinity chromatography after performing Na 2 CO 3 concentration in the size-up step to 0.15-0.6 M.
- FIG. 17 is a diagram related to Example 3, showing cation exchange chromatography purification results for HPV Type 16 and Type 18 L1 proteins.
- FIG. Lane 1 0.5 M NaCl
- lane 2 0.4 M KCl
- lane 3 0.4 M Na 2 CO 3 .
- Lane 18 is a diagram related to Example 3, showing the results of affinity chromatography purification for HPV type 16 protein.
- Lane 1 0.5 M NaCl
- lane 2 0.4 M KCl
- lane 3 0.4 M Na 2 CO 3 .
- Example 19 is a view related to Example 4, which shows the results of evaluation of the stability of HPV antigen according to the type and concentration of salt and reaction temperature in the size-up step.
- Lane 1 0.5 M NaCl
- Lane 2 0.4 M KCl
- Lane 3 0.4 M Na 2 CO 3
- Lane 4 0.15 M NaCl.
- YPDG medium was used to express HPV type 16 L1 and type 18 L1 proteins from the GAL10 promoter.
- yeast extract (Duchefa Biochem, Netherlands) and 2% peptone (Duchefa Biochem, Netherlands) were added to all media, glucose and galactose were added. After inoculating the transformed yeast strain in YPDG medium was cultured using a fermentor (fermentor) at 30 °C, the culture time was not more than 96 hours.
- the yeast cells were mixed with a buffer solution (20 mM sodium phosphate, pH 7.2, 100 mM NaCl, 1.7 mM EDTA, 0.01% Tween 80), and the cells were disrupted with a cell disruptor, and the supernatant was recovered by centrifugation of the disruption solution. . 45% by weight of ammonium sulfate was added to the collected supernatant, followed by centrifugation at high speed (24,000 g) to discard the supernatant, and only the precipitate was recovered.
- a buffer solution (20 mM sodium phosphate, pH 7.2, 100 mM NaCl, 1.7 mM EDTA, 0.01% Tween 80
- the recovered precipitate was measured for protein concentration by BCA assay, 1X PBS-T was added to dilute the concentration of the ammonium salt precipitate to a concentration of 30 mg / mL, and NaCl was added to the final concentration at 0.8 M. After stirring for about 30 minutes, the mixture was left at 4 ° C and incubated for 18 hours.
- the precipitate sample was dialyzed in the size-up buffer to which the four kinds of salts were added, and the incubator at a temperature of 30 ° C. ( ⁇ 2 ° C.) was allowed to stand for 16-26 hours (two hour intervals) or 48 hours for the lowest value. The time zone indicating turbidity was confirmed.
- Insoluble protein removal is a method of increasing the purity of the purified by precipitating impurities at room temperature, the lower the OD value of the supernatant centrifuged after incubation means that more impurities were removed.
- the turbidity value was different according to the salt type of the size-up buffer, but overall, the higher the incubation temperature, the lower the OD 600 nm value. It may be inferred that it is easy, but at too high temperature, there was a problem with protein structure.
- the purification yield of HPV type 16 L1 protein purified by incubation at 30 ° C. and 35 ° C. for 24 hours to remove insoluble protein, respectively was about 2.65. It was mg / L, but the purification yield at 35 ° C. was about 1.24 mg / L, and the purity was also low.
- the incubation time of the insoluble protein was measured at 2 hours interval and 48 hours at 16-26 hours under the respective salt conditions, and as a result, the insoluble protein precipitated over time. It was confirmed that turbidity increased and then maintained at a constant level. Turbidity of the suspension means that impurities are induced to increase the purity. However, since incubation for too long may cause the target protein to precipitate, the incubation time suitable for the removal of insoluble protein is considered to be 21-26 hours.
- the yeast cells of Example 1 were mixed with a buffer solution (20 mM sodium phosphate, pH 7.2, 100 mM NaCl, 1.7 mM EDTA, 0.01% Tween 80), and then the cells were disrupted with a cell disrupter, and then the crushed solution was fast (24,000 g). The supernatant was recovered by centrifugation. 45% by weight of ammonium sulfate was added to the recovered supernatant, followed by centrifugation at high speed (24,000 g) to discard the supernatant and recover only the precipitate.
- a buffer solution (20 mM sodium phosphate, pH 7.2, 100 mM NaCl, 1.7 mM EDTA, 0.01% Tween 80
- the supernatant was recovered by centrifugation. 45% by weight of ammonium sulfate was added to the recovered supernatant, followed by centrifugation at high speed (24,000 g) to discard the supernatant and recover only the precipitate.
- the recovered precipitate was measured for protein concentration by BCA assay, and the concentration of ammonium salt precipitate was diluted to 10 mg / mL-60 mg / mL (10 mg / mL interval) by adding 1X PBS-T. NaCl was added at a final concentration of 0.8 M to the precipitate for each concentration, stirred for about 30 minutes, and left at 4 ° C for incubation for 18 hours. After incubation with NaCl, the suspension was added to the dialysis membrane at each concentration to undergo dialysis with a size-up buffer.
- the size-up buffer of Example 1 was added to dilute the protein concentration to 10 mg / mL or less, and then allowed to stand in a 30 ° C ( ⁇ 2 ° C) incubator and incubated for 24 hours. After 24 hours, the resulting supernatant was recovered by centrifugation at high speed (24,000 g), and the collected supernatant was placed in a dialysis membrane and dialyzed at 4 ° C. with binding buffer (PBS + 0.35 M NaCl pH 7.2, 0.01% Tween 80). It was. After dialysis, the supernatant was filtered by centrifugation at high speed (24,000 g). This filtrate was purified by cation exchange chromatography.
- a 1.6 cm X 5 cm Poly-Prep column (GE healthcare lifescience, USA) filled with P-11 cellulose phosphate resin (Whatman, UK) was run with binding buffer (PBS + 0.5 M NaCl) at 5 times the resin volume. Subject equilibrium was maintained. The dialysis solution was combined by passing through a P-11 column, followed by washing the binding buffer by doubling the resin volume. After washing, 4-5 mL of elution buffer containing 0.6 M, 0.7 M, 0.8 M and 1 M NaCl was flowed into the binding buffer to elute the L1 protein). Fractions identified with the target band were classified to calculate the yield after purification of BCA.
- the concentration conditions of ammonium salt precipitates having high purification yields of HPV antigens range from 25 mg / mL to 65 mg / mL.
- the size-up step is to remove impurities through incubation with a salt.
- a type of salt suitable for HPV VLP antigen purification and to confirm the degree of removal of impurities by salt concentration The experiment was conducted. Table 1 shows the types of common salts.
- the yeast cells of Example 1 After mixing the buffer solution (20 mM sodium phosphate, pH 7.2, 100 mM NaCl, 1.7 mM EDTA, 0.01% Tween 80) to the yeast cells of Example 1, the cells were disrupted by a cell disruptor, and the supernatant solution was centrifuged. Was recovered. 45% by weight of ammonium sulfate was added to the recovered supernatant, centrifuged at high speed (24,000 g), and the supernatant was discarded and only the precipitate was recovered (at this time, the precipitate was added with a small amount of 1X PBS-T buffer to form a suspension).
- buffer solution (20 mM sodium phosphate, pH 7.2, 100 mM NaCl, 1.7 mM EDTA, 0.01% Tween 80
- Protein concentration was measured by BCA assay, and 1X PBS-T was added to dilute the concentration of the ammonium salt precipitate to within 30 mg / mL. NaCl was slowly added to the diluted precipitate with a final concentration of 0.8 M. After stirring for about 30 minutes, the mixture was left at 4 ° C and incubated for 18 hours. After incubation with NaCl, the suspension was placed in a dialysis membrane and dialyzed using the components of Table 2 in the size-up buffer composition. After dialysis was completed, each size-up buffer was added to dilute the protein concentration to 10 mg / mL or less, and then incubated in a 30 ° C. ( ⁇ 2 ° C.) incubator for 24 hours.
- the resultant was centrifuged at high speed (24000 g) to recover the supernatant, and the recovered supernatant was dialyzed at 4 ° C. with binding buffer (PBS + 0.35 M NaCl pH 7.2, 0.01% Tween 80). .
- the supernatant was filtered by dialysis with binding buffer and centrifugation at high speed (24000 g).
- the filtrate was purified by cation exchange chromatography as in Example 2, and only the fractions of high purity were collected and analyzed for yield calculation.
- purification using affinity chromatography is performed based on the salt conditions showing the highest yields of the respective salt types in cation exchange chromatography. The experiment was further performed.
- affinity chromatography maintained equilibrium by flowing binding buffer (PBST with 0.33M NaCl) 10 times the resin volume on a column filled with heparin Sepharose resin (GE healthcare life science, USA). .
- the dialysis solution was combined by passing through a heparin column and washed by pouring an elution buffer containing 2 M NaCl in a linear concentration gradient from 0.33 M NaCl to 0.5 M NaCl at 50 times the resin volume. After washing, the elution buffer containing 2 M NaCl was flowed 20 times the resin volume in a linear concentration gradient from 0.5 M NaCl to 1.5 M NaCl to elute the L1 protein.
- the fractions identified with the target bands were classified and the purification yield was calculated after BCA quantification.
- Affinity chromatography used a 1 mL Heparin column (GE, USA).
- Purification yields were calculated using different types and concentrations of salts using cation exchange chromatography. As a result, purification was not performed at all salt concentration conditions in MgCl 2 , and in other NaCl, KCl, and Na 2 CO 3 , respectively. To 10 were obtained. In addition, affinity chromatography performed also showed a high yield at a high salt concentration of 0.3 M or more, similarly to cation exchange chromatography (FIGS. 11 to 16).
- the samples were quantified by the BCA assay for the highest yield samples for each salt type, and 0.5 ⁇ g of the sample was placed on two 12% acrylamide gels for 150 V, 150 mA, and 1.5 hours. Electrophoresis. One sheet was subjected to silver staining to identify the developed sample, and the other was western blot using commercially available monoclonal antibodies that specifically reacted with HPV 16 and 18 antigens.
- the types of salts showing good effects in preparing HPV type 16 and 18 L1 VLP antigens are NaCl, KCl and Na 2 CO 3 , and the concentration range of these salts is 0.35-0.60 for optimal insoluble protein removal. M could be confirmed.
- the antigen produced according to the salt type and concentration was evaluated for the stability of the antigen by varying the reaction temperature and storage time conditions.
- a size-up process was performed according to the type and concentration of salt to prepare the produced HPV type 16 L1 VLP antigen (0.15 M NaCl, 0.5 M NaCl, 0.4 M KCl, 0.4 M Na 2 CO 3 ).
- the antigen stability was set at 40 ° C. and 60 ° C. and the reaction time was 12, 24 and 36 hours to evaluate the stability of the antigen.
- Antigens were dispensed into new tubes at 150 ⁇ l according to the conditions in Table 3 below. The antigen samples were collected hourly and the status of the antigen was confirmed via Western blot.
- Western blot was performed by quantifying the sample by BCA assay, 0.6 ⁇ g electrophoresis on 12% acrylamide gel for 150 V, 150 mA, 1.5 hours, and then transferred to nitrocellulose membrane. Transcribed samples were identified by color reaction after reaction with commercially available monoclonal antibodies that specifically react with HPV 16 and 18 antigens.
- the antigen samples were confirmed by Western blot according to the temperature. As a result, it was confirmed that the stability of the antigen was maintained at 40 ° C. and 60 ° C. Considering that 40 ° C. and 60 ° C. are harsh temperature conditions, the above results support that the HPV antigen prepared in the preparation method of the present invention can maintain stability as an antigen even at normal refrigeration and freezing temperatures.
Abstract
Description
양이온/음이온 | NO3 - | Cl- | S2- | SO4 2 - | CO3 2 - |
Na+ | NaNO3 | NaCl | Na2S | Na2SO4 | Na2CO3 |
K+ | KNO3 | KCl | K2S | K2SO4 | K2CO3 |
NH4 + | NH4NO3 | NH4Cl | (NH4)2S | (NH4)2SO4 | (NH4)2CO3 |
Mg2 + | Mg(NO3)2 | MgCl2 | MgS | MgSO4 | MgCO3 |
Ba2 + | Ba(NO3)2 | BaCl2 | BaS | BaSO4 | BaCO3 |
Ca2 + | Ca(NO3)2 | CaCl2 | CaS | CaSO4 | CaCO3 |
Pb3 + | Pb(NO3)2 | PbCl2 | PbS | PbSO4 | PbCO3 |
Ag+ | AgNO3 | AgCl | Ag2S | Ag2SO4 | Ag2CO3 |
NaCl | KCl | Na2CO3 | MgCl2 |
0.15M NaCl | 0.15M KCl | 0.15M Na2CO3 | 0.15M MgCl2 |
0.3M NaCl | 0.3M KCl | 0.3M Na2CO3 | 0.3M MgCl2 |
0.4M NaCl | 0.4M KCl | 0.4M Na2CO3 | 0.4M MgCl2 |
0.5M NaCl | 0.5M KCl | 0.5M Na2CO3 | 0.5M MgCl2 |
0.6M NaCl | 0.6M KCl | 0.6M Na2CO3 | 0.6M MgCl2 |
Claims (9)
- 다음의 단계를 포함하는 인유두종 바이러스(HPV)의 L1 바이러스 유사 입자(VLP)의 제조방법:(a) HPV의 L1 단백질을 발현하는 형질전환 효모를 배양하는 단계;(b) 단계 (a)에서 배양된 형질전환 효모의 생산물에 대하여 암모늄 설페이트 침전을 실시하여 침전물을 얻는 단계;(c) 암모늄 설페이트 침전을 실시하여 얻은 침전물에 0.35-0.60 M의 염을 처리하고 인큐베이션 한 후, 형성된 불용성 단백질을 제거하는 단계; 및(d) 단계 (c)의 결과물에 대하여 크로마토그래피를 실시하여 L1 단백질을 얻는 단계.
- 제 1 항에 있어서, 상기 단계 (b)에서 처리되는 암모늄 설페이트의 농도는 40-50 중량%인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 방법은 단계 (b)와 (c) 사이에, 암모늄 설페이트 침전을 실시하여 얻어진 침전물을 염이 포함된 용액에서 인큐베이션 하는 단계를 더 포함하는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 단계 (c)의 암모늄 설페이트 침전을 실시하여 얻은 침전물은 25-65 mg/mL의 농도를 갖는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 단계 (c)의 염은 NaCl, KCl 또는 Na2CO3인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 단계 (c)에서 처리되는 염의 농도는 0.35-0.55 M인 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 단계 (c)는 25-34℃의 온도로 인큐베이션 하는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 단계 (c)는 21-27시간 동안 인큐베이션 하는 것을 특징으로 하는 방법.
- 제 1 항에 있어서, 상기 HPV는 HPV 타입 6a, HPV 타입 6b, HPV 타입 11, HPV 타입 16, HPV 타입 18, HPV 타입 31, HPV 타입 33, HPV 타입 35, HPV 타입 39, HPV 타입 45, HPV 타입 51, HPV 타입 52, HPV 타입 56, HPV 타입 58 및 HPV 타입 68로 구성된 군으로부터 선택되는 것을 특징으로 하는 방법.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2015149330A RU2677336C2 (ru) | 2014-12-26 | 2015-10-12 | Способ получения вирусоподобных частиц папилломавируса человека |
EA201790944A EA201790944A1 (ru) | 2014-12-26 | 2015-10-12 | Способ получения вирусоподобных частиц папилломавируса человека |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140190902 | 2014-12-26 | ||
KR10-2014-0190902 | 2014-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016104923A1 true WO2016104923A1 (ko) | 2016-06-30 |
Family
ID=56150907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/010740 WO2016104923A1 (ko) | 2014-12-26 | 2015-10-12 | 인유두종 바이러스의 바이러스 유사 입자 제조방법 |
Country Status (4)
Country | Link |
---|---|
KR (1) | KR101825996B1 (ko) |
EA (1) | EA201790944A1 (ko) |
RU (1) | RU2677336C2 (ko) |
WO (1) | WO2016104923A1 (ko) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
US6416945B1 (en) * | 1997-09-05 | 2002-07-09 | Medimmune, Inc. | Vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPS) |
US20100255031A1 (en) * | 2007-04-29 | 2010-10-07 | Ying Gu | truncated l1 protein of human papillomavirus type 16 |
KR20120001326A (ko) * | 2010-06-29 | 2012-01-04 | 주식회사 유라코퍼레이션 | 네임테그 일체형 공정박스 |
KR20140018794A (ko) * | 2012-07-30 | 2014-02-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL183781B1 (pl) * | 1994-05-16 | 2002-07-31 | Merck & Co Inc | Sposób wytwarzania szczepionki przeciwko ludzkiemu wirusowi brodawczaków |
ES2381964T3 (es) * | 2003-03-24 | 2012-06-04 | Merck Sharp & Dohme Corp. | Expresión optimizada de L1 de VPH 31 en levadura |
KR100959145B1 (ko) | 2008-03-21 | 2010-05-25 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사 입자의 생산 및 정제 방법 |
MX2011013566A (es) * | 2009-06-19 | 2012-06-28 | Eyegene Inc | Vacunas para cancer cervical. |
-
2015
- 2015-10-12 EA EA201790944A patent/EA201790944A1/ru unknown
- 2015-10-12 KR KR1020150142107A patent/KR101825996B1/ko active IP Right Grant
- 2015-10-12 RU RU2015149330A patent/RU2677336C2/ru active
- 2015-10-12 WO PCT/KR2015/010740 patent/WO2016104923A1/ko active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
US6416945B1 (en) * | 1997-09-05 | 2002-07-09 | Medimmune, Inc. | Vitro method for disassembly/reassembly of papillomavirus virus-like particles (VLPS) |
US20100255031A1 (en) * | 2007-04-29 | 2010-10-07 | Ying Gu | truncated l1 protein of human papillomavirus type 16 |
KR20120001326A (ko) * | 2010-06-29 | 2012-01-04 | 주식회사 유라코퍼레이션 | 네임테그 일체형 공정박스 |
KR20140018794A (ko) * | 2012-07-30 | 2014-02-13 | 중앙대학교 산학협력단 | 인유두종바이러스 바이러스 유사입자의 고효율 정제방법 |
Also Published As
Publication number | Publication date |
---|---|
RU2015149330A3 (ko) | 2018-11-30 |
RU2677336C2 (ru) | 2019-01-16 |
RU2015149330A (ru) | 2018-11-30 |
KR20160080060A (ko) | 2016-07-07 |
KR101825996B1 (ko) | 2018-02-09 |
EA201790944A1 (ru) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Grodzicker et al. | Conditional lethal mutants of adenovirus 2-simian virus 40 hybrids I. host range mutants of Ad2+ ND1 | |
EP2716653B1 (en) | Truncated human papillomavirus type 33 protein l1 | |
Martuscelli et al. | Electron microscopic evidence for linear insertion of bacteriophage Mu-1 in lysogenic bacteria | |
JPS63164896A (ja) | ヒトインタ−フェロンの製造方法及び高純度ヒトインタ−フェロン | |
JPH0515373A (ja) | ヒトゲノムdnaの抽出および精製方法 | |
CN107176977B (zh) | 牛支原体MbovP730蛋白在自然感染和疫苗免疫鉴别中的应用 | |
EP2907821A1 (en) | Method for producing a N-terminaly truncated L1 protein of human papillomavirus (HPV) | |
Takacs et al. | Modification of Escherichia coli membranes in the prereplicative phase of phage T4 infection. Specificity of association and quantitation of bound phage proteins. | |
WO2014038879A1 (ko) | 폐렴 구균 혈청형을 갖는 협막 다당류의 제조방법 | |
Fujii et al. | Characterization of bacteriophage nucleic acids obtained from Clostridium botulinum types C and D | |
CN110358802B (zh) | 一种去除百日咳组分菌毛蛋白2/3内毒素的方法 | |
Ng et al. | Heat treatment of unclarified Escherichia coli homogenate improved the recovery efficiency of recombinant hepatitis B core antigen | |
WO2016104923A1 (ko) | 인유두종 바이러스의 바이러스 유사 입자 제조방법 | |
Sugimoto et al. | Algal-lytic activities encoded by Chlorella virus CVK2 | |
CN113444743A (zh) | 含佐剂基因的羊支原体肺炎二价核酸疫苗的构建方法 | |
Roy et al. | Isolation and properties of poliovirus minus strand ribonucleic acid | |
Waner et al. | Behavior of human cytomegaloviruses in cell cultures of bovine and simian origin | |
Assaf et al. | Unambiguous typing of canine adenovirus isolates by deoxyribonucleic acid restriction-endonuclease analysis. | |
JPH08301891A (ja) | 標的オリゴヌクレオチド被検体の精製方法 | |
Allison et al. | Lysosomal changes in lytic and nonlytic infections with the simian vacuolating virus (SV40) | |
AU2019401729B2 (en) | Purification method for vaccine virus using affinity chromatography | |
Weissmann et al. | Reduction of possible hazards in the preparation of recombinant plasmid DNA | |
WO2020213928A1 (ko) | 보툴리눔 독소의 정제방법 | |
CN104558166B (zh) | 减少抗草鱼呼肠孤病毒多克隆抗体中非特异性抗体的方法 | |
CN107446041B (zh) | 一种抗苹果坏死花叶病毒的抗血清及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15873451 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201790944 Country of ref document: EA |
|
ENP | Entry into the national phase |
Ref document number: 2015149330 Country of ref document: RU Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15873451 Country of ref document: EP Kind code of ref document: A1 |